Friday, 16 Nov 2018

You are here

NK cells and a Potential Role in the Development of PsA vs PsC (Cutaneous Psoriasis)

Human NK cells express multiple receptors that interact with HLA class I molecules which, in turn, suppy peptides that bind HLA-E to form CD94/NKG2A NK receptor ligands. These peptides correspond to -22 to -14 residues in the leader sequences of HLA-A, HLA-B and HLA-C binding to the HLA-E site. Methionine – 21 delivers functional peptides in stark contrast to threonine – 21 which does not. This functional dimorphism allows for division into three groups: -21M/M, -21M/T and -21T/T with respectively decreasing potency of the NKCD94/NKG2A+ receptor. Dr. Chandran et al aimed to determine if these particular haplotypes served as differences between the connection between the HLA class 1 alleles and Psoriatic disease vs the normal population.

Six hundred and sixty four PsA patients, 1155 PsC (cutaneous only Psoriasis) patients vs 3118 controls were studied. One thousand one hundred and seventy seven PsA patients, 659 PsC patients and 1096 controls were self- reported European ethnicity from a single center cohort in Toronto. SNP2HLA was used represent HLA class 1 alleles. Analyses using logistical regression to determine association between HLA B-21 amino acid polymorphisms and different phenotypes in PsC vs controls, PsA vs controls, and PsA vs PsC. Sex and population stratification were used as covariates. This study used reverse line blot techniques and sequence specific oligonucleotide (SSO) probes to type HLA and all analyses were conditioned on HLA B27.

This study found that the PsC patient cohort had significantly lower prevalence of -21M compared to PsA and control patients.

In conclusion, this is one study that indicates a potential NK cell pathogenesis in the development of PsA and shows a possible genetic marker that can differentiate PsA from PsC.

Chandran V, Li Q, Machhar R, Abji F, Ye JY, Nair R, Stuart P, Oikonomopoulou K, Elder JT, Gladman DD, Rahman P. −21 HLA-Class I Dimorphism Differentiates Psoriatic Arthritis (PsA) from Psoriasis without Psoriatic Arthritis (PsC) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/%e2%88%9221-hla-class-i-dimorphism-dif.... Accessed October 18, 2018.

 

https://acrabstracts.org/abstract/%E2%88%9221-hla-class-i-dimorphism-dif...

Add new comment

More Like This

Ixekizumab COAST-V Trial Wins in Axial Spondyloarthritis

Lancet has published the results of a study showing that ixekizumab (an IL-17A inhibitor) yielded significant clinical benefit and radiographic protection when given to NSAID treated patients with radiographic axial spondyloarthritis (AxSpA).

Doubling Down on IL-17 In Psoriatic Arthritis

The monoclonal antibody bimekizumab, which neutralizes both interleukin (IL)-17A and 17F, was effective for both musculoskeletal and skin outcomes in psoriatic arthritis (PsA) in a phase IIb study.

Updates on Psoriatic Arthritis at ACR 2018

I think 2018 was the year that belonged to psoriatic arthritis (although some may argue in favor of immune conditions induced by Checkpoint inhibitors). Many years ago the late Professor Verna Wright in Leeds (UK) was a lone voice for many years describing the clinical subtypes of Psoriatic arthritis as something distinctive from rheumatoid arthritis. For a long time we thought that the treatments for PsA were just the same as RA since we were treating the same problem of synovitis.

Axial Spondylitis Abstracts Roundup

There have been a number of interesting posters and presentations covering the field of axial spondyloarthropathy. I’ve picked out a few points that I found particularly relevant.

Classification Criteria

What is the Future of MTX for Psoriatic Arthritis?

Like most rheumatologists, I retain a deep and abiding love for methotrexate. And with each passing decade since the drug’s ‘re-discovery’ by rheumatology, evidence for a positive trade-off between its benefits and harms has continued to accrue, ensuring its role as the centrepiece of our treatment strategies for rheumatoid arthritis, even as an avalanche of biologics and targeted synthetic DMARDs has swept over us.